Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CRBP
CRBP logo

CRBP News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CRBP News

Corbus Pharmaceuticals Q1 Earnings Beat Expectations

5d agoseekingalpha

Corbus Secures FDA Alignment on CRB-701 Pathway

Apr 07 2026Newsfilter

Corbus Aligns with FDA on CRB-701 Registration Pathway

Apr 07 2026NASDAQ.COM

FDA Approves Corbus' Registrational Study Design

Apr 07 2026Newsfilter

Corbus Pharmaceuticals Reports Q4 2025 Financial Results

Mar 09 2026seekingalpha

Corbus Pharmaceuticals Reports 2025 Financial Results and Clinical Updates

Mar 09 2026Newsfilter

Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management

Dec 27 2025Yahoo Finance

Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers

Dec 19 2025NASDAQ.COM

CRBP Events

05/12 08:10
Corbus CEO Says Strong Momentum for CRB-701 and CRB-913 Programs
"We've continued to build strong momentum with CRB-701 and CRB-913, setting the stage for rapidly approaching inflection points for both the oncology and obesity programs," said Yuval Cohen, Chief Executive Officer of Corbus.

CRBP Monitor News

Corbus Pharmaceuticals surges on CRB-913 trial success

Dec 11 2025

CRBP Earnings Analysis

No Data

No Data

People Also Watch